Patients with relapsed or refractory T-cell lymphoma have limited treatment options. Chimeric antigen receptor (CAR) T-cell therapy has been challenging in these patients because of the state of their T cells. CTX130 is an allogeneic CAR T-cell therapy targeting CD70 on cancerous T cells, offering a potential cell therapy option for these patients.
In a small phase I study led by Swaminathan P. Iyer, MD, Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, presented at the European Hematology Association (EHA) 2022 Congress (Abstract S262), researchers evaluated the safety and efficacy of CTX130 in 17 patients with relapsed or refractory T-cell lymphoma. At the two highest dose levels, the overall response rate was 71% in seven patients, including two complete responses (29%). Responses were seen both in patients with peripheral T-cell lymphoma and transformed cutaneous T-cell lymphoma. The therapy had an acceptable safety profile, with no instances of graft-vs-host disease, and no grade 3 or higher cytokine-release syndrome or immune effector cell–associated neurotoxicity syndrome.
The early results suggest CTX130 is safe and, as a first-in-class allogeneic CAR T-cell therapy, offers clinically meaningful benefits for patients with advanced T-cell lymphoma.
Disclosure: For full disclosures of the study authors, visit library.ehaweb.org.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.